L&C Bio’s Human-Fat Injection Could Fix “Ozempic Face”: Will Gains Hold?
L&C Bio Co., Ltd. (290650.KQ) shares jumped nearly 12% Thursday on plans for an Ozempic face fix made from donated human fat.
The KOSDAQ-listed stock reached 64,600 won intraday, up 11.76%, per Yahoo Finance data, extending a five-day gain of roughly 24%. Investors welcomed the news as a fresh growth avenue beyond the firm's existing skin care line.
An Ozempic Side Effect Becomes a Business Plan
GLP-1 (glucagon-like peptide-1) drugs such as Ozempic drive rapid weight loss. Some users then develop a gaunt, hollowed look known as "Ozempic face," and L&C Bio wants to treat that gap directly.
The market behind that problem is expanding fast. J.P. Morgan Research projects the U.S. patient base for GLP-1 drugs will climb from 12.9 million in 2026 to 30.3 million by 2030, split between type 2 diabetes and obesity patients. Each new obesity patient on an Ozempic-class drug is a potential candidate for facial volume loss, and therefore a potential customer for L&C Bio.
The company's planned product, tentatively named MegaAdipoECM, converts donated human fat into an extracellular matrix scaffold. Patients' own fat cells then repopulate the treated area, restoring volume without synthetic filler.
… Continue reading the full article at the original source below.
